the aid library

LIST OPTIONS

Filter

9288

Sort by:

Direction:

Download (272)

View PDF (367)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (195)

View PDF (171)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (146)

View PDF (473)

Water dilemmas: The cascading impacts of water insecurity in a heating world

Oxfam (2023) CC

Climate-induced water insecurity poses one of the biggest threats to humanity and will lead to more hunger, disease and displacement Oxfam water engineers are having to drill deeper, more expensive and harder-to-maintain water boreholes used by some of the poorest communities around the world, mo... more

Download (160)

View PDF (143)

Public health resource pack for countries experiencing outbreaks of influenza in animals: revised guidance

World Health Organisation (WHO) (2023) C_WHO

This resource pack was developed for the country offices of the World Health Organization and national Public Health institutions, as an overview of the key information needed for advising their Member States in response to questions raised on human health due to influenza outbreaks or detections in... more

Download (178)

View PDF (186)

10 promising practices from the Protection from Sexual Exploitation and Abuse (PSEA) in Europe

United Nations High Commissioner for Refugees UNHCR (2023) CC

UNHCR invested significantly in risk mitigation, prevention and response to sexual exploitation and abuse (SEA) in the Europe region in 2022-2023, in particular in connection with the Ukraine emergency, where the risks were considered high due to the unprecedented scale and speed of displacement, mo... more

Download (214)

View PDF (195)

Target product profiles for animal plasma-derived antivenoms: antivenoms for treatment of snakebite envenoming in sub-Saharan Africa

World Health Organisation (WHO) (2023) C_WHO

This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document: Broad spectrum Pan-African polyvalent antivenoms: products ... more

Download (124)

View PDF (136)

Anuual Report 2022: Lesotho

World Health Organisation (WHO) (2023) C_WHO

This annual report gives an overview of WHO lesotho Country office's undertakings and achievements in the context of an extraordinary health emergency. As we walk another mile this year, may we embrace all lessonst leanred in the previous year, learn from what did not work so well and take on new op... more

Download (133)

View PDF (171)

Principles to guide health system recovery and transformation in Ukraine

World Health Organization WHO (2022) C_WHO

Despite the continuing war in Ukraine, the Government is preparing for the country’s recovery and reconstruction. Given the magnitude of the attacks on the health infrastructure and consequent disruption to health system functioning, reconstruction of the health system is integral to the country�... more

Download (546)

View PDF (811)

Access to medicine Index 2022

Access to Medicine Foundation (2022) C2

Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in- come countries (LMICs). While the COVID-19 pan... more

Download (178)

View PDF (148)

A public health perspective on zero- and low-alcohol beverages

World Health Organisation (WHO) (2023) C_WHO

There is an expanding market of no- and low-alcohol beverages (NoLos). However, their effects on global ethanol consumption and public health are still questioned. Policies and regulations about NoLos’ availability, acceptability and affordability are lacking and evidence about their benefits is l... more

Download (117)

View PDF (422)

Global mortality of snakebite envenoming between 1990 and 2019

Nature Communications (2022) CC

Snakebite envenoming affects millions of people worldwide annually and is a significant source of mortality. Preventing and treating the problem is complex and requires collaboration among the fields of public health, medicine, ecology, and laboratory science. After being removed from the category A... more

Download (116)

View PDF (526)

The social context of schistosomiasis and its control: an introduction and annotated bibliography

Bruun, B.; Aagaard-Hansen, J.; Watts, S. World Health Organization WHO; Institutional Repository for Information Sharing iris (2008) C_WHO

Schistosomiasis is widely recognized as a disease that is socially determined. An understanding of the social and behavioural factors linked to disease transmission and control should play a vital role in designing policies and strategies for schistosomiasis prevention and control. To this must b... more

Download (116)

View PDF (415)

Guide for the Medical, Veterinary and allied Professions

Bishop, G.; Durrheim, D.; Kloeck, P. et al. Department: Agriculture, Foresty and Fisheries - Republic of South Africa (2010) CC

Rabies is a disease of animals but too often the outcome is gauged in terms of human suffering and death. Despite this, in areas of the world where rabies is endemic there is often a lack of communication between veterinary and medical professionals, to the extent that the disease continues to thri... more

Download (240)

View PDF (215)

Addressing violence against women in health policies and protocols in the Americas: A regional status report

World Health Organisation (WHO) (2023) C_WHO

Violence against women and girls is widespread in the Region of the Americas, resulting in enormous consequences for the health and wellbeing of women and girls, their families and communities. These costs are unacceptable and they can be prevented through evidence-based action, including the health... more

Download (115)

View PDF (140)

Clinical management of COVID-19: living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

As of 12 December 2022, over 645 million people worldwide have been diagnosed with COVID-19, with over 6.6 million deaths (4). The Omicron variant, which emerged in late November 2021, and its subvariants, are now the dominant circulating viruses, contributing to the ongoing surge in several countr... more

Download (174)

View PDF (217)

Trends in maternal mortality 2000 to 2020: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division

World Health Organisation (WHO) (2023) C_WHO

Every day in 2020, approximately 800 women died from preventable causes related to pregnancy and childbirth - meaning that a woman dies around every two minutes. Sustainable Development Goal (SDG) target 3.1 is to reduce maternal mortality to less than 70 maternal deaths per 100 000 live births by ... more

Download (131)

View PDF (159)

Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy

Tirados, I.; Esterhuizen, J.; Kovacic, V.; Mangwiro, TNC.; Vale, GA et al. PLOS Neglected Tropical Diseases (2015) CC

Sleeping sickness is controlled by case detection and treatment but this often only reaches less than 75% of the population. Vector control is capable of completely interrupting HAT transmission but is not used because of expense. We conducted a full scale field trial of a refined vector control tec... more

Download (122)

View PDF (336)

The social context of schistosomiasis and its control

Brunn, B.; Aagaard-Hansen, J.; Watts, S. World Health Organization WHO (2008) C_WHO

Download (139)

View PDF (156)

Indicators and questions for monitoring progress on the 2021 Political Declaration on HIV and AIDS — Global AIDS Monitoring 2023

UNAIDS (2022) C_WHO

The indicators and questions in this document are designed for use by national AIDS programmes and partners to assess the state of a country’s HIV and AIDS response, and to measure progress towards achieving national HIV targets. Countries are encouraged to integrate these indicators and questions... more

Download (162)

View PDF (234)

Global antimicrobial resistance and use surveillance system (‎GLASS)‎ report: 2022

World Health Organisation (WHO) (2022) C_WHO

The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) was launched in 2015 to foster AMR surveillance and inform strategies to contain AMR. The system started with surveillance of AMR in bacteria causing common human infections and has expanded its scope to include surveillance... more